These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37147783)

  • 61. Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer.
    Niu M; Valdes S; Naguib YW; Hursting SD; Cui Z
    Mol Pharm; 2016 Jun; 13(6):1833-42. PubMed ID: 27074028
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Modified peroxamide-based reactive oxygen species (ROS)-responsive doxorubicin prodrugs.
    Jafari M; Sriram V; Premnauth G; Merino E; Lee JY
    Bioorg Chem; 2022 Oct; 127():105990. PubMed ID: 35785552
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Encapsulation of doxorubicin prodrug in heat-triggered liposomes overcomes off-target activation for advanced prostate cancer therapy.
    Pereira S; Ma G; Na L; Hudoklin S; Kreft ME; Kostevsek N; Al-Jamal WT
    Acta Biomater; 2022 Mar; 140():530-546. PubMed ID: 34954416
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells.
    Rui M; Qu Y; Gao T; Ge Y; Feng C; Xu X
    Int J Nanomedicine; 2017; 12():217-237. PubMed ID: 28115844
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Synergistic Combination Chemotherapy of Lung Cancer: Cisplatin and Doxorubicin Conjugated Prodrug Loaded, Glutathione and pH Sensitive Nanocarriers.
    Jin Y; Wang Y; Liu X; Zhou J; Wang X; Feng H; Liu H
    Drug Des Devel Ther; 2020; 14():5205-5215. PubMed ID: 33268983
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Human serum albumin-based doxorubicin prodrug nanoparticles with tumor pH-responsive aggregation-enhanced retention and reduced cardiotoxicity.
    Zhang B; Wan S; Peng X; Zhao M; Li S; Pu Y; He B
    J Mater Chem B; 2020 May; 8(17):3939-3948. PubMed ID: 32236239
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Stimuli-responsive PEGylated prodrugs for targeted doxorubicin delivery.
    Xu M; Qian J; Liu X; Liu T; Wang H
    Mater Sci Eng C Mater Biol Appl; 2015 May; 50():341-7. PubMed ID: 25746279
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Enhanced bioreduction-responsive diselenide-based dimeric prodrug nanoparticles for triple negative breast cancer therapy.
    He X; Zhang J; Li C; Zhang Y; Lu Y; Zhang Y; Liu L; Ruan C; Chen Q; Chen X; Guo Q; Sun T; Cheng J; Jiang C
    Theranostics; 2018; 8(18):4884-4897. PubMed ID: 30429875
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
    Yang S; Shim MK; Kim WJ; Choi J; Nam GH; Kim J; Kim J; Moon Y; Kim HY; Park J; Park Y; Kim IS; Ryu JH; Kim K
    Biomaterials; 2021 May; 272():120791. PubMed ID: 33831739
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Synergistic action of doxorubicin and 7-Ethyl-10-hydroxycamptothecin polyphosphorylcholine polymer prodrug.
    Wu Z; Li S; Cai Y; Chen F; Chen Y; Luo X
    Colloids Surf B Biointerfaces; 2020 May; 189():110741. PubMed ID: 32032928
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Fabrication of redox-responsive doxorubicin and paclitaxel prodrug nanoparticles with microfluidics for selective cancer therapy.
    Ma X; Özliseli E; Zhang Y; Pan G; Wang D; Zhang H
    Biomater Sci; 2019 Jan; 7(2):634-644. PubMed ID: 30534690
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
    Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
    J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A bottlebrush-architectured dextran polyprodrug as an acidity-responsive vector for enhanced chemotherapy efficiency.
    Zhang T; Wang Y; Ma X; Hou C; Lv S; Jia D; Lu Y; Xue P; Kang Y; Xu Z
    Biomater Sci; 2020 Jan; 8(1):473-484. PubMed ID: 31755481
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Nitric oxide nano-reactor DNMF/PLGA enables tumor vascular microenvironment and chemo-hyperthermia synergetic therapy.
    Wang R; Cheng L; He L; Du C; Wang H; Peng B; Yu X; Liu W; Luo W; Ran H; Yang L
    J Nanobiotechnology; 2024 Mar; 22(1):110. PubMed ID: 38481281
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Acid-sensitive lipidated doxorubicin prodrug entrapped in nanoemulsion impairs lung tumor metastasis in a breast cancer model.
    Dos Santos Câmara AL; Nagel G; Tschiche HR; Cardador CM; Muehlmann LA; de Oliveira DM; Alvim PQ; Azevedo RB; Calderón M; Figueiró Longo JP
    Nanomedicine (Lond); 2017 Aug; 12(15):1751-1765. PubMed ID: 28703043
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Design and Evaluation of a Carrier-Free Prodrug-Based Palmitic-DEVD-Doxorubicin Conjugate for Targeted Cancer Therapy.
    Yang SB; Lee DN; Lee JH; Seo M; Shin DW; Lee S; Lee YH; Park J
    Bioconjug Chem; 2023 Feb; 34(2):333-344. PubMed ID: 36735902
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Vitamin-H Channeled Self-Therapeutic P-gp Inhibitor Curcumin-Derived Nanomicelles for Targeting the Tumor Milieu by pH- and Enzyme-Triggered Hierarchical Disassembly.
    Das M; Joshi A; Devkar R; Seshadri S; Thakore S
    Bioconjug Chem; 2022 Feb; 33(2):369-385. PubMed ID: 35015523
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
    Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
    Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A pH-sensitive nanotherapeutic system based on a marine sulfated polysaccharide for the treatment of metastatic breast cancer through combining chemotherapy and COX-2 inhibition.
    Zhang T; Liu H; Li Y; Li C; Wan G; Chen B; Li C; Wang Y
    Acta Biomater; 2019 Nov; 99():412-425. PubMed ID: 31494294
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Copper-based metal-organic framework impedes triple-negative breast cancer metastasis via local estrogen deprivation and platelets blockade.
    Wang S; Yin N; Li Y; Xiang T; Jiang W; Zhao X; Liu W; Zhang Z; Shi J; Zhang K; Guo X; Si P; Liu J
    J Nanobiotechnology; 2022 Jul; 20(1):313. PubMed ID: 35794596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.